Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations.
Journal
NPJ precision oncology
ISSN: 2397-768X
Titre abrégé: NPJ Precis Oncol
Pays: England
ID NLM: 101708166
Informations de publication
Date de publication:
31 Jul 2024
31 Jul 2024
Historique:
received:
25
08
2023
accepted:
09
07
2024
medline:
1
8
2024
pubmed:
1
8
2024
entrez:
31
7
2024
Statut:
epublish
Résumé
Cancer cells with BRCA1/2 deficiencies are sensitive to poly (ADP-ribose) polymerase (PARP) inhibitors. We evaluated the efficacy of talazoparib in DNA-Damage Repair (DDR)-altered patients. In this phase II trial, patients were enrolled onto one of four cohorts based on molecular alterations: (1) somatic BRCA1/2, (2) other homologous recombination repair pathway, (3) PTEN and (4) germline BRCA1/2. The primary endpoint was a clinical benefit rate (CBR): complete response, partial response or stable disease ≥24 weeks. 79 patients with a median of 4 lines of therapy were enrolled. CBR for cohorts 1-4 were: 32.5%, 19.7%, 9.4% and 30.6%, respectively. PTEN mutations correlated with reduced survival and a trend towards shorter time to progression.Talazoparib demonstrated clinical benefit in selected DDR-altered patients. PTEN mutations/loss patients derived limited clinical benefit. Further study is needed to determine whether PTEN is prognostic or predictive of response to PARP inhibitors.
Identifiants
pubmed: 39085400
doi: 10.1038/s41698-024-00634-6
pii: 10.1038/s41698-024-00634-6
doi:
Types de publication
Journal Article
Langues
eng
Pagination
166Informations de copyright
© 2024. The Author(s).
Références
Birkelbach, M. et al. Detection of impaired homologous recombination repair in NSCLC cells and tissues. J. Thorac. Oncol. 8, 279–286 (2013).
pubmed: 23399959
pmcid: 3573529
doi: 10.1097/JTO.0b013e31827ecf83
Hennessy, B. T. et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol. 28, 3570–3576 (2010).
pubmed: 20606085
pmcid: 2917312
doi: 10.1200/JCO.2009.27.2997
George, J. et al. Nonequivalent gene expression and copy number alterations in high-grade serous ovarian cancers with BRCA1 and BRCA2 mutations. Clin. Cancer Res. 19, 3474-3484 (2013).
Gorringe, K. L. et al. Copy number analysis identifies novel interactions between genomic loci in ovarian cancer. PLoS One 5, e11408 (2010).
Konishi, H. et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proc. Natl. Acad. Sci. USA 108, 17773–17778 (2011).
pubmed: 21987798
pmcid: 3203756
doi: 10.1073/pnas.1110969108
Fong, P. C. et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123–134 (2009).
pubmed: 19553641
doi: 10.1056/NEJMoa0900212
Kummar, S. et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin. Cancer Res. 18, 1726–1734 (2012).
pubmed: 22307137
pmcid: 3306481
doi: 10.1158/1078-0432.CCR-11-2821
Stefansson, O. A. et al. Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res. 11, R47 (2009).
pubmed: 19589159
pmcid: 2750106
doi: 10.1186/bcr2334
Buisson, R. et al. Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat. Struct. Mol. Biol. 17, 1247–1254 (2010).
pubmed: 20871615
pmcid: 4094107
doi: 10.1038/nsmb.1915
Chen, P. et al. Association of common PALB2 polymorphisms with breast cancer risk: a case-control study. Clin. Cancer Res. 14, 5931–5937 (2008).
pubmed: 18794107
doi: 10.1158/1078-0432.CCR-08-0429
Gilardini Montani, M. S. et al. ATM-depletion in breast cancer cells confers sensitivity to PARP inhibition. J. Exp. Clin. Cancer Res. 32, 95 (2013).
pubmed: 24252502
pmcid: 4176289
doi: 10.1186/1756-9966-32-95
Evans, K. W. et al. A population of heterogeneous breast cancer patient-derived xenografts demonstrate broad activity of PARP inhibitor in BRCA1/2 wild-type tumors. Clin. Cancer Res. 23, 6468–6477 (2017).
pubmed: 29093017
pmcid: 5679124
doi: 10.1158/1078-0432.CCR-17-0615
Howlett, N. G. et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 297, 606–609 (2002).
pubmed: 12065746
doi: 10.1126/science.1073834
Mathew, C. G. Fanconi anaemia genes and susceptibility to cancer. Oncogene 25, 5875–5884 (2006).
pubmed: 16998502
doi: 10.1038/sj.onc.1209878
Chu, E. C. & Tarnawski, A. S. PTEN regulatory functions in tumor suppression and cell biology. Med Sci. Monit. 10, RA235–RA241 (2004).
pubmed: 15448614
Mendes-Pereira, A. M. et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol. Med. 1, 315–322 (2009).
pubmed: 20049735
pmcid: 3378149
doi: 10.1002/emmm.200900041
McEllin, B. et al. PTEN loss compromises homologous recombination repair in astrocytes: implications for glioblastoma therapy with temozolomide or poly(ADP-ribose) polymerase inhibitors. Cancer Res. 70, 5457–5464 (2010).
pubmed: 20530668
pmcid: 2896430
doi: 10.1158/0008-5472.CAN-09-4295
Gupta, A. et al. Cell cycle checkpoint defects contribute to genomic instability in PTEN deficient cells independent of DNA DSB repair. Cell Cycle 8, 2198–2210 (2009).
pubmed: 19502790
doi: 10.4161/cc.8.14.8947
Peng, G. et al. Genome-wide transcriptome profiling of homologous recombination DNA repair. Nat. Commun. 5, 3361 (2014).
pubmed: 24553445
doi: 10.1038/ncomms4361
Lord, C. J. & Ashworth, A. BRCAness revisited. Nat. Rev. Cancer 16, 110–120 (2016).
pubmed: 26775620
doi: 10.1038/nrc.2015.21
Pilie, P. G. et al. PARP inhibitors: extending benefit beyond BRCA-mutant cancers. Clin. Cancer Res. 25, 3759–3771 (2019).
pubmed: 30760478
doi: 10.1158/1078-0432.CCR-18-0968
Murai, J. et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 72, 5588–5599 (2012).
pubmed: 23118055
pmcid: 3528345
doi: 10.1158/0008-5472.CAN-12-2753
Hoy, S. M. Talazoparib: first global approval. Drugs 78, 1939–1946 (2018).
pubmed: 30506138
doi: 10.1007/s40265-018-1026-z
Shen, Y. et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin. Cancer Res. 19, 5003–5013 (2013).
pubmed: 23881923
pmcid: 6485449
doi: 10.1158/1078-0432.CCR-13-1391
Murai, J. et al. Stereospecific PARP trapping by BMN 673 and comparison with Olaparib and Rucaparib. Mol. Cancer Ther. 13, 433–443 (2014).
pubmed: 24356813
doi: 10.1158/1535-7163.MCT-13-0803
Golan, T. et al. Maintenance Olaparib for germline BRCA-mutated metastatic pancreatic cancer. N. Engl. J. Med. 381, 317–327 (2019).
pubmed: 31157963
pmcid: 6810605
doi: 10.1056/NEJMoa1903387
Heeke, A. L., et al. Prevalence of homologous recombination-related gene mutations across multiple cancer types. JCO Precis. Oncol. 2018 https://doi.org/10.1200/PO.17.00286 (2018).
Robinson, D. et al. Integrative clinical genomics of advanced prostate cancer. Cell 162, 454 (2015).
pubmed: 28843286
doi: 10.1016/j.cell.2015.06.053
Agarwal, N. et al. Plain language summary of the design of the TALAPRO-2 study comparing talazoparib and enzalutamide versus enzalutamide and placebo in men with metastatic castration-resistant prostate cancer. Future Oncol. 18, 2979–2986 (2022).
doi: 10.2217/fon-2022-0389
Agarwal, N. et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 402, 291–303 (2023).
pubmed: 37285865
doi: 10.1016/S0140-6736(23)01055-3
Tung, N. M. et al. TBCRC 048: phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J. Clin. Oncol. 38, 4274–4282 (2020).
pubmed: 33119476
doi: 10.1200/JCO.20.02151
Gruber, J. J. et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes. Nat. Cancer 3, 1181–1191 (2022).
pubmed: 36253484
pmcid: 9586861
doi: 10.1038/s43018-022-00439-1
Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852–861 (2011).
pubmed: 21862407
doi: 10.1016/S1470-2045(11)70214-5
de Bono, J. et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov. 7, 620–629 (2017).
pubmed: 28242752
pmcid: 5905335
doi: 10.1158/2159-8290.CD-16-1250
Mateo, J. et al. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373, 1697–1708 (2015).
pubmed: 26510020
pmcid: 5228595
doi: 10.1056/NEJMoa1506859
Shen, W. H. et al. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128, 157–170 (2007).
pubmed: 17218262
doi: 10.1016/j.cell.2006.11.042
Minami, D. et al. Synergistic effect of olaparib with combination of cisplatin on PTEN-deficient lung cancer cells. Mol. Cancer Res. 11, 140–148 (2013).
pubmed: 23239809
doi: 10.1158/1541-7786.MCR-12-0401
Westin, S. N. et al. Phase Ib dose expansion and translational analyses of olaparib in combination with capivasertib in recurrent endometrial, triple-negative breast, and ovarian cancer. Clin. Cancer Res. 27, 6354–6365 (2021).
pubmed: 34518313
pmcid: 8639651
doi: 10.1158/1078-0432.CCR-21-1656
Bian, X., et al. PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene (2017).
Juvekar, A. et al. Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov. 2, 1048–1063 (2012).
pubmed: 22915751
pmcid: 3733368
doi: 10.1158/2159-8290.CD-11-0336
Matulonis, U. A. & Monk, B. J. PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? Ann. Oncol. 28, 443–447 (2017).
pubmed: 28057663
doi: 10.1093/annonc/mdw697
Johnson, A. et al. The right drugs at the right time for the right patient: the MD Anderson Precision Oncology Decision Support Platform. Drug Discov. Today 20, 1433–1438 (2015).
pubmed: 26148707
pmcid: 5648066
doi: 10.1016/j.drudis.2015.05.013
Djordjevic, B. et al. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod. Pathol. 25, 699–708 (2012).
pubmed: 22301702
pmcid: 3341518
doi: 10.1038/modpathol.2011.208
Meric-Bernstam, F. et al. Influence of biospecimen variables on proteomic biomarkers in breast cancer. Clin. Cancer Res. 20, 3870–3883 (2014).
pubmed: 24895461
pmcid: 4112583
doi: 10.1158/1078-0432.CCR-13-1507
Detre, S., Saclani Jotti, G. & Dowsett, M. A “quickscore” method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J. Clin. Pathol. 48, 876–878 (1995).
pubmed: 7490328
pmcid: 502883
doi: 10.1136/jcp.48.9.876
Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213–219 (2013).
pubmed: 23396013
pmcid: 3833702
doi: 10.1038/nbt.2514
Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet 46, 912–918 (2014).
pubmed: 25017105
pmcid: 4753679
doi: 10.1038/ng.3036
Ye, K. et al. Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads. Bioinformatics 25, 2865–2871 (2009).
pubmed: 19561018
pmcid: 2781750
doi: 10.1093/bioinformatics/btp394
Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754–1760 (2009).
pubmed: 19451168
pmcid: 2705234
doi: 10.1093/bioinformatics/btp324
DePristo, M. A. et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat. Genet 43, 491–498 (2011).
pubmed: 21478889
pmcid: 3083463
doi: 10.1038/ng.806
Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256–259 (2014).
pubmed: 25301631
pmcid: 4354858
doi: 10.1126/science.1256930
Olshen, A. B. et al. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557–572 (2004).
pubmed: 15475419
doi: 10.1093/biostatistics/kxh008
Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10, 1–10 (1989).
pubmed: 2702835
doi: 10.1016/0197-2456(89)90015-9
Thall, P. F., Simon, R. M. & Estey, E. H. Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Stat. Med 14, 357–379 (1995).
pubmed: 7746977
doi: 10.1002/sim.4780140404
Kaplan, E. L. & Meier Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53, 457–481 (1958).
doi: 10.1080/01621459.1958.10501452
Piha-Paul, S. A., et al. Supplemental Data for A Phase II Study of Talazoparib Tosylate in Advanced Cancer Patients with Somatic and Germline (Not Breast or Ovarian Cancer) Alterations of BRCA1/2, Mutations/Deletions/Amplification in Other Homologous Recombination Repair Pathway Genes and PTEN or PTEN loss. https://doi.org/10.52519/00133 .